Crossmark

Current approaches to incorporation of radium-223 in clinical practice

Crossref DOI link: https://doi.org/10.1038/s41391-017-0020-y

Published Online: 2018-01-03

Published Print: 2018-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Parker, Chris

Heidenreich, Axel

Nilsson, Sten

Shore, Neal
License Information

Text and Data Mining valid from 2018-01-03
More Information

Article History

Received: 17 July 2017

Accepted: 16 September 2017

First Online: 3 January 2018

Compliance with ethical standards

:

: C.P. has research support from Bayer and has received honoraria from and is an advisory board member and speaker for Bayer, Janssen, and AAA. A.H. is a consultant for Amgen, Astellas, Bayer, and Ipsen; is an advisory board member for Astellas, Ipsen, Janssen, and Sanofi; has received honoraria from Amgen, Astellas, Bayer, Ferring, Ipsen, Janssen, Pfizer, and Sanofi; and has received research grants from Amgen, Astellas, and Sanofi. S.N. is an advisory board member for and has received honoraria from Bayer. N.S. is a consultant for and has received research grants from Amgen, Astellas, Bayer, Dendreon, Ferring, Janssen, Pfizer, Sanofi, and Tolmar.